New
HealthMore in Health→
Early Durvalumab Study Explores Stage I Triple-Negative Breast Cancer
Key Takeaways
- POP-DURVA studies two doses of durvalumab before standard treatment.
- It enrolls patients with stage I triple-negative tumors smaller than two centimeters.
- The primary endpoint is pathological complete response at surgery.
- The phase 2 trial seeks an early activity signal and does not replace current standards of care.
DE
DT Editorial Team··via medicalxpress.com